Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 13NIH 2INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NETWORK × peginterferon alfa-2b × Clear all
NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

California Cancer Consortium

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡